The roller coaster ride to the first GLP-1 obesity drug While approved first as a drug for diabetes, very early on in its development, when Knudsen first began work on liraglutide she wondered if the same drug could also be used as a treatment of obesity (Molteni, Chen)
Gastrointestinal symptoms such as nausea, constipation, and indigestion are most common and usually subside as your body adjusts
Please email us and we will do what we can to help you in your situation
PMID: 38963021
The report projects that sales of orforglipron will reach $16 billion in 2031, whereas retatrutide will produce revenue of $30 billion that year, which includes $10 billion in obesity drug sales and $20 billion in diabetes drug sales
GLP-1 helps regulate your blood sugar, slow your digestion, and control your appetite